Sumanta (Monty) Kumar Pal, MD, FASCO

Dr. Monty Pal discusses the historical role of the International Metastatic Renal Cell Database Consortium (IMDC) risk criteria in guiding treatment decisions for advanced renal cell carcinoma (RCC) and explains why its influence has evolved in the current therapeutic landscape.

Dr. Monty Pal introduces the program by outlining the evolving treatment landscape for advanced renal cell carcinoma (RCC) and emphasizing the importance of translating clinical trial evidence and guideline recommendations into individualized patient care.